Hikma Farmacêutica (Portugal) S.A has informed the MHRA that the Patient Information Leaflet (PIL) contained within batch CB0033 of Gemcitabine 2g/52.6ml concentrate for solution for infusion does not contain the side effects of serious skin reactions.
Similar Posts
Medicines: get scientific advice from MHRA
A summary of the types of scientific advice available at the MHRA, the process for getting advice and the fees involved.
Decentralised manufacture: Clinical Trial Authorisation (CTA) and Good Clinical Practice (GCP)
Guidance for clinical trials that use Decentralised Manufactured Investigational Medicinal Products (IMPs).
National Patient Safety Alert: Class 1 Medicines Recall Notification: Recall of Quetiapine Oral Suspension (unlicensed medicine), manufactured by Eaststone Limited due to a potential for overdosing, NatPSA/2026/002/MHRA
Eaststone Limited is initiating a recall of all batches of quetiapine oral suspension products due to a potential risk of overdose, which could have consequences for the safety of patients.
Field Safety Notices: 15 – 19 December 2025
List of Field Safety Notices (FSNs) for week 15 – 19 December 2025
MHRA Safety Roundup: October 2025
Summary of the latest safety advice for medicines and medical device users
Class 3 Medicines Recall: Sun Pharmaceutical Industries Limited, Fingolimod SUN 0.5mg hard capsules, EL(25)A/49
Sun Pharma UK Limited is conducting a precautionary recall of a single batch of Fingolimod SUN 0.5 mg hard capsules due to reports of capsule breakage on removing from the blister. No other batches of Fingolimod SUN 0.5mg hard capsules are impacted.